Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol in Primary Ovarian Insufficiency
NCT05410093Unknown
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Feb 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of resveratrol in primary ovarian insufficiency (POI) (2 arms), sponsored by Affiliated Hospital of Nantong University. Primary endpoints: Follicle-stimulating hormone at 3 months and Luteinizing hormone at 3 months. Status: unknown.
02
Drugs
resveratrol
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05410093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410093.